← Search & browse all drugs
GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY › Alpha-adrenoreceptor antagonists
tamsulosin and solifenacin
G04CA53
Forms & Strengths
- Capsule (fixed-dose combination): tamsulosin hydrochloride 0.4 mg / solifenacin succinate 6 mg
Adult Dosing
- Benign prostatic hyperplasia (BPH) with storage symptoms: 1 capsule (0.4 mg / 6 mg) orally once daily taken approximately 30 minutes after the same meal
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of moderate-to-severe storage symptoms (frequency, urgency) associated with benign prostatic hyperplasia (BPH) in men
Mechanism of Action
- Tamsulosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck, improving urine flow
- Solifenacin is a competitive muscarinic receptor antagonist (primarily M3) that reduces detrusor muscle tone, decreasing bladder urgency and storage symptoms
Contraindications
- Hypersensitivity to tamsulosin, solifenacin, or any component
- Urinary retention
- Gastric retention
- Uncontrolled narrow-angle glaucoma
- Severe hepatic impairment (Child-Pugh C) or severe renal impairment (CrCl < 30 mL/min) if taking strong CYP3A4 inhibitors
- Patients undergoing hemodialysis
Adverse Reactions
- Dry mouth
- Constipation
- Dizziness
- Ejaculatory disorder (retrograde ejaculation)
- Somnolence
- Blurred vision
- Urinary tract infection
- Orthostatic hypotension
Drug Interactions
- Strong CYP3A4 inhibitors (e.g., ketoconazole) increase exposure to both tamsulosin and solifenacin; dosage adjustments may be necessary
- Other anticholinergic agents may increase the risk of severe dry mouth, constipation, and urinary retention
- Strong CYP2D6 inhibitors (e.g., paroxetine) increase exposure to tamsulosin
- Other alpha-1 blockers can enhance hypotensive effects leading to dizziness or orthostasis
Curated Content: Needs Vetting Before Put to Clinical Use